
Moleculin Biotech Stock (MBRX) Dives 10% on Clinical Trial Results
Moleculin Biotech (MBRX) stock took a beating on Wednesday after the clinical-stage pharmaceutical company released results from a Phase 1B/2 study of Annamycin. This study evaluated the safety and effectiveness of Annamycin as a treatment for soft tissue sarcoma lung metastases.
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Moleculin Biotech Chairman and CEO Walter Klemp said, 'Looking ahead, we believe these results strongly support further evaluations of Annamycin for the treatment of STS lung mets and we look forward to exploring opportunities to potentially bring this important treatment option to patients.'
While the clinical trial data was positive, it doesn't appear to be as strong as investors hoped. As a result, shares of MBRX stock were down 10.71% as of Wednesday morning. That extends its 55.88% year-to-date drop and 82.82% 12-month decline.
Is Moleculin Biotech Stock a Buy, Sell, or Hold?
Turning to Wall Street, the analysts' consensus rating for Moleculin Biotech is Strong Buy, based on three Buy ratings over the past three months. With that comes an average MBRX stock price target of $10.67, representing a potential 1,268.65% upside for the shares.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Insider
28 minutes ago
- Business Insider
Lululemon downgraded to Market Perform from Outperform at CICC
CICC analyst Mingkai Zhuang downgraded Lululemon (LULU) to Market Perform from Outperform with a $280.49 price target Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>


Business Insider
an hour ago
- Business Insider
RoboSense Technology Company., Ltd (2498) Receives a Buy from DBS
In a report released today, Elizabelle Pang from DBS reiterated a Buy rating on RoboSense Technology Company., Ltd (2498 – Research Report), with a price target of HK$45.00. The company's shares closed last Friday at HK$32.60. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Pang is a 2-star analyst with an average return of 0.4% and a 54.44% success rate. Pang covers the Consumer Cyclical sector, focusing on stocks such as Tesla, Hesai Group Sponsored ADR, and Bayerische Motoren Werke Aktiengesellschaft. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for RoboSense Technology Company., Ltd with a HK$45.00 average price target.


Business Insider
2 hours ago
- Business Insider
Boeing preps to resume deliveries to China, Reuters reports
A new Boeing (BA) 737 MAX painted with Xiamen Airlines' regalia left for China on Friday, Lisa Barrington and Dan Catchpole of Reuters reports, citing flight records on FlightRadar24. This comes after deliveries to Chinese customers were abruptly halted in early April as the U.S. and China edged toward a trade war. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>